IN8bio, Inc. Common Stock
INABIN8bio, Inc. (INAB) is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of resistant and hard-to-treat cancers. The company leverages its proprietary gamma delta T cell platform to engineer and enhance immune responses against tumors, aiming to improve patient outcomes through its advanced immunotherapy approaches.
Company News
IN8bio announced peer-reviewed clinical results from its Phase 1 trial of INB-200 (DeltEx DRI) published in The Journal of Clinical Oncology. The chemotherapy-resistant gamma-delta T cell therapy demonstrated a median progression-free survival of 16.1 months in repeat-dose patients, more than double the standard of care benchmark of 6.9 months, w...
IN8bio announced presentations at major medical conferences in May-June 2026, including new clinical data on its gamma-delta T cell therapies at ASCO. The company will host an R&D Day on May 21, 2026, showcasing advances in its T cell engager platform and clinical programs, particularly highlighting survival benefits observed in glioblastoma pati...
IN8bio, Inc. (Nasdaq: INAB) announced that its Compensation Committee granted nonqualified stock options for 11,800 shares of common stock to two new employees on April 1, 2026, as an inducement for employment. The options will vest over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.
INB.bio, a direct advertiser in dietary and wellness supplements operating across 15 countries, announced its 2026 expansion strategy targeting Tanzania and three to five additional countries in Africa and Southeast Asia. The company plans to launch an AI-powered affiliate CRM platform and a turnkey partner program. The expansion capitalizes on a...
IN8bio announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin, who has served as COO since December 2021, will continue overseeing company operations as IN8bio advances its clinical pipeline. The company highlighted recent preclinical data for INB-619, its pan-γδ T cell engag...
